First-line treatment with sotorasib, bevacizumab, and chemotherapy demonstrated activity in patients with KRAS G12C-mutant, advanced NSCLC First-line treatment with sotorasib, bevacizumab, and chemotherapy demonstrated activity in patients with KRAS G12C-mutant, advanced non-small cell lung cancer (NSCLC), according to research presented...

Abstract KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell lung cancer (NSCLC) in Western countries. Of the various KRAS mutants, KRAS G12C is the most common variant (~40%), representing 10-13% of advanced non-squamous NSCLC. Recent regulatory...

Despite recent therapeutic advances, the adjuvant treatment of non-small cell lung cancer (NSCLC) remains a challenge. Reducing the risk of recurrence is sti Introduction Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC)...

FDA designates olomorasib and pembrolizumab as breakthrough therapy for advanced KRAS G12C-mutant lung cancer, showing promising response rates in trials The FDA has granted breakthrough therapy designation to olomorasib in combination with pembrolizumab (Keytruda) for the treatment of unresectable advanced...

The FDA has granted breakthrough therapy designation and orphan drug designation to D3S-001, a KRAS G12C inhibitor The US Food and Drug Administration (FDA) has granted breakthrough therapy designation and orphan drug designation to D3S-001, a KRAS G12C inhibitor. The...

Adagrasib Shows Improved Progression-Free Survival Over Docetaxel in KRAS G12C-Mutated NSCLC Study A recent study has revealed that adagrasib, a targeted therapy, offers significant progression-free survival (PFS) benefits for patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS...

A recent study has revealed that adagrasib, a targeted […] This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as...

… metastatic non-small cell lung cancer (NSCLC) harboring a … In the United States, lung cancer is considered the leading … -mutant Non-Small Cell Lung Cancer (SUNRAY-02). Clinicaltrials.gov … chatgpt.com Key Statistics for Lung Cancer. American Cancer Society. … 9/4/2025...

The FDA has granted Breakthrough Therapy and Orphan Drug designation to D3S-001 for the treatment of KRAS G12C-mutated cancers The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to D3S-001 for the treatment of adults with KRAS G12C-mutated...